Skip to Main Content

Author Details

Krister Wennerberg
University of Copenhagen
1994
148
50
PMIDPaper TitleJournal TitlePublished Year
37996540Robust scoring of selective drug responses for patient-tailored therapy selection.Nat Protoc2024
36423211PI3Kβ inhibition enhances ALK-inhibitor sensitivity in ALK-rearranged lung cancer.Mol Oncol2023
38040674Standardized assays to monitor drug sensitivity in hematologic cancers.Cell Death Discov2023
37325550Synthetic lethal interaction between WEE1 and PKMYT1 is a target for multiple low-dose treatment of high-grade serous ovarian carcinoma.NAR Cancer2023
37458534PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells.Mol Oncol2023
37148882A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids.Dev Cell2023
37178002Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data.Nucleic Acids Res2023
36519325<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.Haematologica2023
36508699Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.Blood2023
34789538Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia.Cancer Discov2022
35963891Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells.Sci Rep2022
36170112Protocol to utilize fresh uncultured human lung tumor cells for personalized functional diagnostics.STAR Protoc2022
36081565Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status.Front Oncol2022
34921013Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors.Cancer Res2022
35158794Pancreatic Cancer Organoids in the Field of Precision Medicine: A Review of Literature and Experience on Drug Sensitivity Testing with Multiple Readouts and Synergy Scoring.Cancers (Basel)2022
35166670Comprehensive and unbiased multiparameter high-throughput screening by compaRe finds effective and subtle drug responses in AML models.Elife2022
34472587Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments.Brief Bioinform2022
33300000Minimal information for Chemosensitivity assays (MICHA): A next-generation pipeline to enable the FAIRification of drug screening experiments.bioRxiv2021
33792631Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells.Blood Adv2021
33750001Multi-modal meta-analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor.Mol Syst Biol2021
33608276Patient-tailored design for selective co-inhibition of leukemic cell subpopulations.Sci Adv2021
34467250Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments.Cell Rep Med2021
34302041Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia.NPJ Precis Oncol2021
34343245Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer.Brief Bioinform2021
34145035CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis.Cancer Res2021
34083538Crowdsourced mapping of unexplored target space of kinase inhibitors.Nat Commun2021
32055842Exploration of databases and methods supporting drug repurposing: a comprehensive survey.Brief Bioinform2021
30566623Interactive visual analysis of drug-target interaction networks using Drug Target Profiler, with applications to precision medicine and drug repurposing.Brief Bioinform2020
32071079Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.J Biol Chem2020
31974521A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening.Commun Biol2020
31649109Atypical KRAS<sup>G12R</sup> Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.Cancer Discov2020
33321085Mitochondria in Their Prime Drive Venetoclax Response in Acute Myeloid Leukemia.Cancer Cell2020
32967973Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma.Sci Transl Med2020
32678289KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia.Leukemia2020
32651543Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition.Leukemia2020
32931743Immunogenomic Landscape of Hematological Malignancies.Cancer Cell2020
32187448Improved detection of differentially represented DNA barcodes for high-throughput clonal phenomics.Mol Syst Biol2020
32119072Breeze: an integrated quality control and data analysis application for high-throughput drug screening.Bioinformatics2020
32553168Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.Cell Rep2020
32231398Identification of novel regulators of STAT3 activity.PLoS One2020
31439679Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types.Haematologica2020
31595974ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.J Pathol2020
30530703Anagrelide for Gastrointestinal Stromal Tumor.Clin Cancer Res2019
31905951Human Tumor-Derived Matrix Improves the Predictability of Head and Neck Cancer Drug Testing.Cancers (Basel)2019
31889236Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment.Clin Transl Med2019
31829282Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer.Clin Epigenetics2019
32368721Prediction of drug combination effects with a minimal set of experiments.Nat Mach Intell2019
31617439Novel Screening Method Identifies PI3Kα, mTOR, and IGF1R as Key Kinases Regulating Cardiomyocyte Survival.J Am Heart Assoc2019
31238897Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma.BMC Cancer2019
31521622Chemogenomic Analysis of the Druggable Kinome and Its Application to Repositioning and Lead Identification Studies.Cell Chem Biol2019
  • 1 - 50 of 148

Recommended Authors

Peter S Winter
Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School
Career Start Year 2014
Number of shared co-authors 3
Brent M Kuenzi
Moffitt Cancer Center
Career Start Year 2014
Number of shared co-authors 0
Mehdi Bouhaddou
J. David Gladstone Institutes
Career Start Year 2014
Number of shared co-authors 3
Wail Ba-Alawi
Princess Margaret Cancer Centre, University Health Network, University Ave.
Career Start Year 2013
Number of shared co-authors 1
Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 3
Nehme El-Hachem
Centre Hospitalier Universitaire Sainte-Justine Research Centre
Career Start Year 2011
Number of shared co-authors 1
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 1
Pichai Raman
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2006
Number of shared co-authors 3
Armand Bankhead
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 2005
Number of shared co-authors 3
Sourav Bandyopadhyay
University of California San Francisco
Career Start Year 2004
Number of shared co-authors 1
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 2
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 9
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 2
Trever G Bivona
University of California san francisco
Career Start Year 2002
Number of shared co-authors 4
Mariano J Alvarez
Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center
Career Start Year 2000
Number of shared co-authors 14
Christopher D Willey
University of Alabama at Birmingham
Career Start Year 2000
Number of shared co-authors 3
Mathew J Garnett
Wellcome Sanger Institute
Career Start Year 1998
Number of shared co-authors 18
Monika A Davare
Oregon Health Sciences University
Career Start Year 1998
Number of shared co-authors 5
Bissan Al-Lazikani
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 3
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 3
Jeremy S Caldwell
Sirna Therapeutics a former subsidiary of Merck & Co., Inc.
Career Start Year 1994
Number of shared co-authors 0
Michael Peyton
Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center
Career Start Year 1994
Number of shared co-authors 8
Michael A White
University of Georgia
Career Start Year 1994
Number of shared co-authors 8
Ultan McDermott
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 4
Marc Ferrer
National Institutes of Health, National Center for Advancing Translational Sciences
Career Start Year 1992
Number of shared co-authors 4
Aykut Uren
Georgetown University Medical Center
Career Start Year 1991
Number of shared co-authors 3
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 17
Enzo Medico
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Career Start Year 1988
Number of shared co-authors 1
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 7
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 33

Collaborators

Tero Aittokallio
Institute for Molecular Medicine Finland (FIMM), University of Helsinki
Co-authored papers 55
Olli Kallioniemi
Karolinska Institute
Co-authored papers 31
Jing Tang
University of Helsinki
Co-authored papers 25
Suleiman A Khan
Helsinki Institute for Information Technology (HIIT), Aalto University
Co-authored papers 12
Alok Jaiswal
Indian Institute of Technology Kanpur
Co-authored papers 9
Samuel Kaski
Aalto University
Co-authored papers 7
Peddinti Gopalacharyulu
Technical Research Centre of Finland
Co-authored papers 5
Gustavo Stolovitzky
IBM T.J. Watson Research Center
Co-authored papers 4
Emanuel F Petricoin
Center for Applied Proteomics and Molecular Medicine, George Mason University
Co-authored papers 4
Sarang S Talwelkar
Co-authored papers 4
Mariaelena Pierobon
Center for Applied Proteomics and Molecular Medicine, George Mason University
Co-authored papers 4
Imre Västrik
Co-authored papers 3
Mehmet G??nen
Department of Infectious Diseases and Clinical Microbiology, Koc University
Co-authored papers 3
Janna Saarela
Co-authored papers 3
Jaana Oikkonen
University of Helsinki
Co-authored papers 3
Michael Ohlmeyer
Atux Iskay LLC
Co-authored papers 3
Guanghua Xiao
The University of Texas Southwestern Medical Center
Co-authored papers 2
Yang Xie
Quantitative Biomedical Research Center
Co-authored papers 2
Julio Saez-Rodriguez
Institute of Computational Biomedicine, Heidelberg University
Co-authored papers 2
Xiaowei Zhan
Southwestern Medical Center, University of Texas
Co-authored papers 2
Anna V??h??rautio
University of Helsinki
Co-authored papers 2
Garry L Corthals
Co-authored papers 2
Kerstin Bunte
University of Groningen
Co-authored papers 2
David Tamborero
Universitat Pompeu Fabra
Co-authored papers 2
Tao Wang
University of Texas Southwestern Medical Center
Co-authored papers 2
Thea Norman
Bill & Melinda Gates Foundation
Co-authored papers 2
Yuanfang Guan
University of Michigan ann arbor
Co-authored papers 2
Tapio Pahikkala
University of Turku
Co-authored papers 2
Markus Perola
Co-authored papers 2
Brian J Druker
Oregon Health & Science University
Co-authored papers 2
Release 1.2